READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/immunocellular/.

Immunotherapies are being widely investigated as a way to develop highly specific anticancer therapies. The goal of most of these immunotherapies is to create a population of killer T cells that are programmed to destroy tumor cells.

The Stem-to-T-Cell research program, exhibits superiority to the existing standard of care. The company is approaching a key point in its development programs and the results from the upcoming milestone should enable the company to focus on promising therapies with the highest potential both in terms of efficacy and market size.

Review upcoming product milestones a get a financial review here: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/immunocellular/.

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 475739

"/> ImmunoCellular, Innovative Cellular Platform, and Pipeline Review « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
MarketersMEDIA Year End Sale is Finally Back! Get up to 70% OFF on your press releases. Hurry! Limited time only.
Click Here
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / ImmunoCellular, Innovative Cellular Platform, and Pipeline Review

ImmunoCellular, Innovative Cellular Platform, and Pipeline Review

Share This Press Release

NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on ImmunoCellular Therapeutics, Ltd. (NYSE American: IMUC), a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

The company is focusing resources on advancing its research-stage Stem-to-T-Cell program in collaboration with leading academic researchers and contract laboratories. IMUC is also continuing to explore opportunities to partner its development-stage programs.

In June, ImmunoCellular received a Deficiency Letter indicating that the Company is not in compliance with the stockholder's equity requirement of the NYSE American Company Guide. As required, the Company submitted a plan to the NYSE American advising of actions it plans to undertake, to regain compliance with the continued listing standards by December 23, 2018.

See how the company is trying to resolve NYSE American issues, and analysts target price: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/immunocellular/.

Immunotherapies are being widely investigated as a way to develop highly specific anticancer therapies. The goal of most of these immunotherapies is to create a population of killer T cells that are programmed to destroy tumor cells.

The Stem-to-T-Cell research program, exhibits superiority to the existing standard of care. The company is approaching a key point in its development programs and the results from the upcoming milestone should enable the company to focus on promising therapies with the highest potential both in terms of efficacy and market size.

Review upcoming product milestones a get a financial review here: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/immunocellular/.

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 475739

NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on ImmunoCellular Therapeutics, Ltd. (NYSE American: IMUC), a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

The company is focusing resources on advancing its research-stage Stem-to-T-Cell program in collaboration with leading academic researchers and contract laboratories. IMUC is also continuing to explore opportunities to partner its development-stage programs.

In June, ImmunoCellular received a Deficiency Letter indicating that the Company is not in compliance with the stockholder's equity requirement of the NYSE American Company Guide. As required, the Company submitted a plan to the NYSE American advising of actions it plans to undertake, to regain compliance with the continued listing standards by December 23, 2018.

See how the company is trying to resolve NYSE American issues, and analysts target price: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/immunocellular/.

Immunotherapies are being widely investigated as a way to develop highly specific anticancer therapies. The goal of most of these immunotherapies is to create a population of killer T cells that are programmed to destroy tumor cells.

The Stem-to-T-Cell research program, exhibits superiority to the existing standard of care. The company is approaching a key point in its development programs and the results from the upcoming milestone should enable the company to focus on promising therapies with the highest potential both in terms of efficacy and market size.

Review upcoming product milestones a get a financial review here: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/immunocellular/.

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 475739

Source URL: https://marketersmedia.com/immunocellular-innovative-cellular-platform-and-pipeline-review/240846

Source: AccessWire

Release ID: 240846

Our Client

Subscribe and Recieve exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2017 MarketersMedia – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).